CJC-1295 no DAC 5mg + IPA 5mg

CJC-1295 no DAC 5mg + Ipamorelin 5mg: Comprehensive Research Guide

FOR RESEARCH USE ONLY. This two-component material is supplied solely for controlled analytical and laboratory research. It is not for human or veterinary use, food, cosmetic, diagnostic, therapeutic, bodybuilding or performance-enhancement purposes.

CJC-1295 no DAC 5mg + Ipamorelin 5mg is a supplier-defined research blend combining nominally equal masses of a modified growth hormone-releasing factor fragment and the pentapeptide growth hormone secretagogue ipamorelin. The components address different receptor systems: modified GRF(1-29) is studied as a growth hormone-releasing hormone receptor (GHRHR) agonist, whereas ipamorelin is studied as an agonist of the ghrelin/growth hormone secretagogue receptor (GHS-R1a). This dual-pathway design makes the blend relevant to receptor cross-talk, pituitary signaling, time-course and analytical-mixture research. It does not establish synergy, clinical effectiveness or safe personal use.

The catalog term “CJC-1295 no DAC” requires care. It is commonly used for a short modified GRF(1-29) analogue without the albumin-reactive Drug Affinity Complex found in CJC-1295 With DAC, but it is not a sufficiently precise chemical identity on its own. Researchers should define the exact sequence and substitutions from the lot certificate and confirm them analytically. A blend is also not a new single molecule: each component retains its own identity, ionization, degradation pathways, receptor pharmacology and assay response.

Component identity and molecular properties

The nominal “5mg + 5mg” label describes target amounts, not a molecular formula and not necessarily corrected peptide content. Counterions, water and residual solvents can contribute to gross mass. Because the two peptides differ greatly in size, molar ratio is not the same as mass ratio. Quantitative experimental design should calculate each component independently from qualified content results rather than assuming equal molarity or treating total vial mass as active peptide mass.

The absence of DAC chemistry is analytically important. A non-DAC modified GRF should not form the characteristic maleimide-thiol albumin conjugate expected from the DAC form. Intact-mass analysis, sequence-supporting fragmentation and explicit terminal-modification evidence should distinguish the two. Product name, retention time or nominal vial amount alone is insufficient.

Mechanistic research framework

1. GHRH-receptor signaling

The modified GRF component is intended to model GHRHR activation in pituitary somatotroph systems. GHRHR is a class B G-protein-coupled receptor that commonly signals through G_s, adenylyl cyclase, cyclic AMP and protein kinase A, with downstream changes in calcium handling, transcription and regulated growth hormone release. Early structure-activity work on GRF(1-29) analogues demonstrated that substitutions can alter receptor affinity, proteolytic stability and duration of action.^[2][3] Those findings do not validate an unspecified commercial sequence.

2. Ghrelin-receptor agonism

Ipamorelin is a pentapeptide growth hormone secretagogue. In primary rat pituitary cells and animal models, it released growth hormone through a GHRP-like receptor pathway; the original report described relative selectivity compared with GHRP-2 and GHRP-6 under the tested conditions.^[4] The relevant receptor is now designated GHS-R1a, the ghrelin receptor, a class A GPCR expressed in pituitary, hypothalamic and peripheral tissues.^[5] Selectivity in early assays does not mean that a material is clinically safe or free of off-target effects.

3. Convergent secretagogue signaling

GHRH-pathway agonists and GHRP/ghrelin-pathway agonists can produce more-than-additive growth hormone responses in some experimental settings. A controlled study in normal men found synergy between submaximal GHRP and GHRH challenges.^[6] This supports a mechanistic hypothesis for dual-pathway experiments, not a guaranteed property of this exact blend. The magnitude and even presence of interaction can depend on ligand identity, concentration, timing, species, endocrine state and somatostatin tone.

4. Calcium and second-messenger integration

GHRHR signaling is commonly associated with cAMP/PKA activity, while GHS-R1a can couple to phospholipase C, inositol phosphate and intracellular calcium pathways. An interaction study should measure receptor-proximal signals for each pathway and include single-component arms. A larger downstream growth hormone signal from the mixture cannot by itself distinguish pharmacodynamic interaction from concentration error, assay saturation or time-dependent priming.

5. Pulsatile endocrine output

Growth hormone secretion is episodic and shaped by GHRH, somatostatin, ghrelin-related signaling, feedback and circadian factors. Sparse sampling can therefore misclassify amplitude, pulse number or total exposure. Time-series research should prespecify sampling density, baseline duration, pulse-detection method and primary endpoint. Downstream IGF-I is delayed and nonspecific; it should not be used as the sole evidence of direct receptor action.

6. Feedback and desensitization

Repeated or sustained stimulation may recruit receptor internalization, altered coupling, somatostatin feedback or changes in GH/IGF-axis sensitivity. Concentration-response curves should be repeated across relevant time points rather than assuming that an acute signal predicts a sustained response. Washout and recovery arms can help separate reversible signaling adaptation from chemical degradation.

7. Mixture-specific analytical effects

Co-formulated peptides can compete for surfaces, change recovery, overlap chromatographically or generate different ion-suppression patterns. Apparent biological “synergy” should not be interpreted until the exposure of each component has been verified in the assay matrix. Stability, adsorption and aggregation should be assessed for the blend and for each component alone.

Research applications and evidence limits

Dual-receptor assay design

The blend can be used to develop experiments that compare GHRHR and GHS-R1a signaling. A rigorous matrix includes vehicle, each component alone, the mixture, qualified reference agonists, receptor-negative cells and receptor-selective antagonism or genetic perturbation. Isobologram, response-surface or factorial designs are more informative than comparing only one mixture concentration with untreated controls.

Pituitary-cell and endocrine time-course models

Primary pituitary cultures or validated somatotroph models may be used to explore secretagogue response, calcium dynamics and growth hormone release. Species differences and culture conditions can substantially affect results. The classic ipamorelin paper reported in vitro and animal pharmacology, while human evidence for ipamorelin remains limited and does not validate the present combination.^[4]

Interaction and combination analysis

“Synergy” is a quantitative conclusion, not a synonym for combining two ingredients. Researchers should define an additivity model in advance, test a range of ratios and concentrations, and report uncertainty. Published GHRH/GHRP interaction studies used other ligands and specific protocols; extrapolation to modified GRF plus ipamorelin requires direct testing.^[6]

Analytical-method development

The different molecular sizes and structures make this mixture useful for examining chromatographic separation, mass-spectrometric selectivity, recovery and component-specific stability. A release or identity method should resolve both intact peptides and relevant degradants. One dominant peak can conceal a lower-response component, and UV area percentages cannot be converted directly to an equal mass ratio without response-factor justification.

Safety-signal and impurity research

FDA has highlighted limited clinical information, physicochemical-characterization gaps, peptide-related impurities, aggregation and immunogenicity concerns for compounded ipamorelin products. Its 2024 advisory materials concluded that available evidence did not adequately support safety and effectiveness and noted serious adverse events in an intravenous postoperative-ileus study, with uncertain causality for reported deaths.^[7][8] These findings support conservative hazard assessment, not personal experimentation.

Anti-doping method research

WADA identifies CJC-1295 among GHRH analogues and ipamorelin among growth hormone secretagogues prohibited at all times in sport.^[9] Accredited anti-doping work may require validated detection targets, chain-of-custody procedures and current prohibited-list review. A research-use label does not remove obligations under sports, import, occupational-safety or controlled-research rules.

Experimental design and quality controls

1. Define both test articles. Record exact sequence, salt form, terminal modifications, lot, nominal amount, content basis and storage history for each component.
2. Confirm chemical identity. Use intact LC-HRMS and sequence-supporting MS/MS for modified GRF and ipamorelin; demonstrate absence of a DAC linker when that distinction matters.
3. Quantify components separately. Apply qualified calibration and component-specific response factors. Do not infer a 1:1 mass ratio from one integrated chromatogram.
4. Include single-component arms. Vehicle, modified GRF alone, ipamorelin alone and blend arms are the minimum basis for an interaction claim.
5. Control receptor specificity. Use receptor-negative cells, selective pathway blockers or genetic controls to separate GHRHR and GHS-R1a responses.
6. Measure time courses. Collect receptor-proximal, growth hormone and downstream markers at biologically justified intervals.
7. Control the matrix. Evaluate adsorption, protease activity, pH, ionic strength, albumin, thiols and ion suppression in the actual system.
8. Predefine statistics. State the additivity model, primary endpoint, replication unit, exclusion criteria and multiplicity plan before interpreting synergy.

Analytical quality-control considerations

• Identity: orthogonal intact-mass and MS/MS evidence for both peptides, including noncanonical ipamorelin residues and the modified GRF termini.
• Purity profile: a separation capable of resolving both components and relevant truncation, oxidation, deamidation, isomerization and aggregation products.
• Content and ratio: independently calibrated results with uncertainty, counterion and water basis stated.
• Method performance: specificity, accuracy, precision, linearity, range, recovery, carryover, robustness and matrix effects documented for both analytes.
• Stability: stability-indicating data in the actual container and matrix, including freeze-thaw and adsorption assessments when scientifically relevant.
• Lot documentation: current CoA with methods, specifications, units, integration rules and acceptance criteria. No universal purity, sterility, endotoxin or shelf-life claim follows from the catalog name.

Laboratory handling and stability

Handle as a research chemical with incompletely characterized hazards. Use trained personnel, task-appropriate protective equipment, controlled weighing practices and an institutionally approved risk assessment. Follow the lot label, CoA and safety data sheet for storage, protect the sealed container from uncontrolled moisture and light, and document excursions.

This page intentionally provides no solution-preparation, dosing or administration instructions. Any analytical solution should be governed by a laboratory-approved, matrix-specific SOP. Record solvent or buffer, pH, concentration basis, container, temperature, mixing and elapsed time. Establish stability with a method that measures each intact component and relevant degradants; visual clarity alone is not evidence of identity, potency or stability.

Frequently asked questions

1. What is CJC-1295 no DAC 5mg + Ipamorelin 5mg?

It is a two-component research mixture: a supplier-defined modified GRF(1-29) analogue without DAC chemistry and the pentapeptide GHS-R1a agonist ipamorelin. The label describes nominal mass, not a new molecule or equal molar quantities.

2. Is “CJC-1295 no DAC” the same as CJC-1295 With DAC?

No. The DAC form contains an albumin-reactive linker designed for covalent thiol association. A non-DAC modified GRF lacks that group and has different mass, reaction behavior and exposure characteristics. Confirm the exact lot identity analytically.

3. Does the blend prove a synergistic effect?

No. Different GHRH and GHRP ligands have interacted synergistically in some controlled studies, but synergy for this exact formulation, ratio, matrix and endpoint must be demonstrated directly using single-component controls and a prespecified additivity model.

4. Is ipamorelin an approved or established treatment?

No approved indication or clinical-use claim is represented here. FDA has described limited evidence and safety and characterization concerns for compounded ipamorelin-related substances. Early receptor, animal or proof-of-concept studies do not establish routine clinical benefit or safe self-use.

5. Can a single HPLC purity number characterize the mixture?

No. The two analytes can have different chromatographic and detector responses. Identity, content, ratio, related substances and stability require component-specific, qualified methods and orthogonal mass-spectrometric evidence.

6. Can this page provide dosing, injection, reconstitution or stacking advice?

No. The product is limited to controlled laboratory research. It provides no instructions for personal preparation, administration, dosage, cycles or combinations. Qualified researchers must follow approved institutional protocols and applicable law.

7. What is the most important control in a blend experiment?

Both single-component arms are essential. Without modified GRF alone and ipamorelin alone, a mixture response cannot be assigned to one receptor pathway or assessed for additivity, antagonism or synergy. Chemical exposure should also be verified in the assay matrix.

Related research navigation

• CJC-1295 With DAC — albumin-binding GHRH analogue for DAC comparison.
• CJC-1295 Without DAC — single-component modified GRF research material.
• Ipamorelin — single-component GHS-R1a agonist research material.
• Sermorelin acetate — GHRH(1-29)-related comparator.
• Tesamorelin — structurally distinct GHRH analogue.
• IGF-1 LR3 — downstream IGF-axis research material.
• BPC-157 — unrelated peptide control for assay-specificity studies.
• Epithalon — short-peptide analytical comparison.
• Terms of Service — site terms and research-use conditions.

References

1. National Center for Biotechnology Information. PubChem Compound Summary: Ipamorelin, CID 9831659.
2. Rivier J, Rivier C, Galyean R, et al. Potent long-acting growth hormone releasing factor analogues. Ann N Y Acad Sci. 1988;527:44-50. PMID 3133968.
3. GRF analogs and fragments: correlation between receptor binding, activity and structure. PMID 1656403.
4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
5. International Union of Pharmacology. LVI. Ghrelin receptor nomenclature, distribution, and function. PMID 16382107.
6. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone-releasing peptide stimulates GH release in normal men and acts synergistically with GHRH. J Clin Endocrinol Metab. 1990;70(4):975-982. PMID 2108187.
7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
8. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing: Ipamorelin. October 29, 2024.
9. World Anti-Doping Agency. World Anti-Doping Code: Prohibited List.

Final research-use disclaimer

FOR RESEARCH USE ONLY. CJC-1295 no DAC 5mg + Ipamorelin 5mg is a laboratory research mixture, not a drug, medicine, supplement, food, cosmetic, diagnostic or medical device. It is not for human or veterinary use and is not intended to diagnose, prevent, mitigate, cure or treat any condition. Published findings involving other GHRH or GHRP ligands do not establish the behavior, effectiveness or safety of this exact blend. Qualified researchers are responsible for lawful procurement, institutional review, test-article verification, experimental design, occupational safety, anti-doping compliance and disposal.